Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates
Chemistry – A European Journal · 06.06.2024 · 30 (32)
DOI: 10.1002/chem.202400217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, online erschienen am 03.05.2024. Verfasst von Nicolás Montesdeoca und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry and Biochemistry, Ruhr-University Bochum, Universitätsstrasse 150, 44780, Bochum, Germany. Hauptthemen laut MEDLINE: Rhenium, Antineoplastic Agents, Coordination Complexes, Apoptosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds der Chemischen Industrie, Aventis Foundation.
Abstract (Originalsprache)
Cancer is one of the deadliest diseases worldwide. Chemotherapy remains one of the most dominant forms for anticancer treatment. Despite their clinical success, the used chemotherapeutic agents are associated with severe side effect and pharmacological limitations. To overcome these drawbacks there is a need for the development of new types of chemotherapeutic agents. Herein, the chemical synthesis and biological evaluation of dinuclear rhenium(I) complexes as potential chemotherapeutic drug candidates are proposed. The metal complexes were found to be internalized by an energy dependent endocytosis pathway, primary accumulating in the mitochondria. The rhenium(I) complexes demonstrated to induce cell death against a variety of cancer cells in the micromolar range through apoptosis. The lead compound showed to eradicate a pancreatic carcinoma multicellular tumor spheroid at micromolar concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry and Biochemistry, Ruhr-University Bochum, Universitätsstrasse 150, 44780, Bochum, Germany.
- School of Chemistry, University of Hyderabad, Hyderabad, 500 046, India.
ORCID-Profile: Johannes Karges
Förderung
- Fonds der Chemischen Industrie
- Aventis Foundation
Zitieren
APA
Montesdeoca, N., Borkar, R. L., Sathiyendiran, M., & Karges, J. (2024). Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates. Chemistry – A European Journal, 30(32). https://doi.org/10.1002/chem.202400217
Vancouver
Montesdeoca N, Borkar RL, Sathiyendiran M, Karges J. Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates. Chemistry – A European Journal. 2024;30(32). doi:10.1002/chem.202400217
BibTeX
@article{Montesdeoca2024,
author = {Montesdeoca, Nicolás and Borkar, Reema L and Sathiyendiran, Malaichamy and Karges, Johannes},
title = {Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates},
journal = {Chemistry – A European Journal},
year = {2024},
volume = {30},
number = {32},
doi = {10.1002/chem.202400217}
}
EUVIMED